Access Biotechnology, established in 2019, invests in biopharma companies developing transformative therapies for conditions with high unmet needs. With a broad investment scope across therapeutic areas and stages, the company emphasizes long-term growth, technical rigor, and collaboration. It has a portfolio of over 30 investments and more than 5 exits, showcasing its commitment to advancing human health.
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →